Ensysce Biosciences Receives Nasdaq Delisting Notice Due to Minimum Stockholders' Equity Deficiency

On May 21, 2026, Ensysce Biosciences, Inc. received a deficiency notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC. The notice states that the company is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum of $2.5 million in stockholders' equity as of the period ended March 31, 2026. As a result of this non-compliance, Ensysce is subject to potential delisting. The company has 45 days, or until July 6, 2026, to submit a formal plan to Nasdaq outlining how it intends to regain compliance. If Nasdaq accepts the plan, the company may be granted an extension of up to 180 days from the date of the notice to meet the requirements. Should the plan be rejected, Ensysce has the option to appeal the decision before a Nasdaq Hearings Panel. The company has stated its intention to submit a compliance plan within the required timeframe and is actively exploring options to address the equity shortfall, though there is no guarantee of a successful outcome.